multiply the number of replication nuclei 5 . Prion replication can be started with the equivalent of one molecule of PrP Sc (ref. 6 ). This high level of sensitivity has enabled detection PrP Sc in blood and urine of experimentally inoculated animals [7] [8] [9] [10] [11] .
Here we establish a quantitative PMCA (qPMCA) procedure to estimate the PrP Sc concentration in various samples. The method is based on the observation that there is a direct relationship between the quantity of PrP Sc in a given sample and the number of PMCA cycles and rounds necessary for its detection. To establish the method and minimize variability owing to the presence of other components in the tissue or fluid sample, we first partially purified PrP Sc using a procedure involving precipitation in the presence of sarkosyl, as described previously 12 . Using this protocol, more than 90% PrP Sc is recovered and corresponds to full-length PrP Sc . To estimate the PrP Sc concentration in our stock solution, we deglycosylated partially purified PrP Sc and determined its concentration by comparison to the signal for known quantities of recombinant prion protein via western blotting and enzyme-linked immunosorbent assay (ELISA) (data not shown). Then we spiked various amounts of partially purified PrP Sc (1 × 10 −8 to 1 × 10 −19 g) into normal hamster brain homogenate and subjected the samples to serial rounds of 144 PMCA cycles. We determined the number of PMCA rounds required to produce a PrP Sc signal detectable by western blot. For the signal to be considered 'positive' it had to be at least five times greater than the densitometric signal of the background. We then plotted the quantity of PrP Sc added to the tube versus the number of PMCA rounds needed for detection (Fig. 1) Prion diseases are transmissible neurodegenerative disorders affecting humans and various animals 1 . The infectious agent, prion, is composed by a misfolded form of the prion protein (PrP Sc ) that propagates in the absence of nucleic acid. The unprecedented nature of the infectious agent and the recent appearance of new forms of transmissible prion diseases with devastating consequences, pose a considerable risk for human health 1 . One important objective in prion research is to detect and quantify small amounts of PrP Sc present in various samples, for both research and practical applications 2, 3 . Quantification of prions will allow estimation of the concentration of infectious material in diverse samples, which will be important for risk assessment and implementation of regulatory measures to prevent prion spreading.
Prions accumulate in large quantities in the brain, but small amounts of PrP Sc exist in many tissues and biological fluids even at early stages of the presymptomatic period [1] [2] [3] [4] . PrP Sc can be detected with high sensitivity by PMCA 5 . PMCA is a cyclical process, conceptually analogous to PCR, that takes advantage of the nucleationdependent prion conversion to accelerate the process by using ultrasound waves to (a) Aliquots with the indicated amounts of PrP Sc were subjected to serial rounds of PMCA (144 cycles each) using standard conditions, and PrP Sc was detected by western blotting using the 3F4 antibody. All samples, except the normal brain homogenate (NBH) used as a migration control were digested with proteinase K (PK). (b) Western blots from five independent experiments (as the example shown in a) were analyzed by densitometry, and the last detectable signal after each PMCA round was plotted, yielding a standard calibration curve to estimate PrP Sc amounts in hamster samples. Error bars, s.e.m. (n = 5).
of PMCA rounds required to detect an unknown sample, we could estimate the quantity of PrP Sc originally present in the sample.
We used the qPMCA methodology to estimate PrP Sc concentration in various tissues and biological fluids of scrapie-affected hamsters. We collected samples from brain, spleen, blood and urine from five hamsters exhibiting the clinical signs of the disease after intraperitoneal inoculation with strain 263K prions. As described above, we partially purified PrP Sc by sarkosyl precipitation to remove components that may affect PMCA efficiency. After centrifugation, we resuspended the pellets directly in healthy hamster brain homogenate and subjected them to serial rounds of 144 PMCA cycles. From three positive spleen samples, PrP Sc was detectable after two rounds of PMCA for two samples and after the third round for the third sample (Fig. 2) . Extrapolation from the calibration curve (Fig. 1b) enabled us to estimate that the average concentration of PrP Sc in the 'symptomatic' spleen was 20 pg g −1 of tissue ( Table 1) . As controls, we subjected various samples of spleen and brain from healthy hamsters to the same procedure. We observed no PrP Sc signal after six rounds of PMCA in any of the control samples (Fig. 2) , indicating that under the experimental conditions used, we detected no spontaneous generation of PrP Sc .
We also analyzed PrP Sc concentrations in other tissues and fluids ( Table 1) . As expected, the brain contained the highest amount of PrP Sc , which was readily detectable by western blotting without the need for PMCA (data not shown). We separated blood samples into plasma and buffy coat; using qPMCA we calculated a concentration of PrP Sc of 13 and 260 fg ml −1 of blood, respectively (Table 1) . Finally, we estimated PrP Sc concentration in urine as 0.2 fg ml −1 . These results indicate that spleen, buffy coat, plasma and urine from symptomatic hamsters respectively contain approximately 10 6 , 10 8 , 2 × 10 9 and 10 11 times less PrP Sc than the brain. These proportions, however, likely change dramatically at different stages of the disease. We are currently using qPMCA to assess the dynamic changes in PrP Sc concentration in various tissues and fluids during the progression of the disease from the initial infection to the onset of the clinical disease. The principle of qPMCA is applicable to prions from any strain or species, but the calibration curve and the dynamic range of detection will likely be different and have to be empirically determined for specific samples.
PMCA has contributed to understanding the mechanism of prion replication, the nature of the infectious agent and the detection of small quantities of PrP Sc in biological samples 13 . qPMCA may have many scientific and practical applications to estimate PrP Sc concentration. The technology may be useful to diagnose disease, develop prion decontamination procedures, identify drugs to prevent the formation and eliminate PrP Sc , quantify the extent of prion contamination in medical or environmental materials and may be used to guide regulatory measures to prevent further spread of prion diseases. Control samples of normal (noninfected) spleen homogenate (samples NS1-6) and brain homogenate (samples NB1-4) were subjected to the same PMCA procedure to assess the rate of spontaneous appearance of PrP Sc reactivity. Normal brain homogenate (NBH) not digested with proteinase K (PK) was used as a migration control. *, incomplete digestion of normal cellular prion protein (PrP C ) with proteinase K, which sometimes occurs after PMCA and is distinguishable from PrP Sc by the unchanged molecular weight. online methods Sample preparation. Syrian hamsters were intraperitoneally inoculated with strain 263K prions and monitored for the appearance of clinical signs, using a standard scale, as previously described 14 . When disease was confirmed, hamsters were killed by CO 2 inhalation, and brains, spleen and blood were collected. Before killing the hamsters, urine was collected using metabolic cages, as described previously 11 . Brain or spleen homogenates were prepared at 10% (wt/vol) in PBS (pH 7.2) plus Complete cocktail of protease inhibitors (Roche). The samples were clarified by a 45-s, low-speed centrifugation (450g). Blood samples were obtained directly from the heart in tubes containing citrate. Plasma and buffy coat were separated by centrifugation in ficoll gradient, as described 7 . The samples of normal brain homogenate used for PMCA substrate were obtained after perfusing hamsters with PBS and 5 mM EDTA. Solutions of 10% normal brain homogenate were made in conversion buffer (PBS without Ca 2+ and Mg 2+ with 150 mM NaCl, 1.0% triton X-100 and Complete protease inhibitors). Debris was removed by a 45-s, low-speed centrifugation (450g) in an Eppendorf centrifuge.
